231. Alpha-1-antitrypsin deficiency Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 93 Drugs : 77 - (DrugBank : 8) / Drug target genes : 10 - Drug target pathways : 36

Drugs and their primary sponsors and trial info
(4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile   
   pH Pharma Inc.
      2020   Phase 2   EUCTR2019-002501-22-GB   United Kingdom;
4-PBA   
   University of Florida
      2001   Phase 2   NCT00067756   United States;
ADS-001   
   Arrowhead Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2018-003385-14-AT   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2018-003385-14-DE   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-003385-14-GB   Canada;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-003385-14-SE   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003385-14-IE   Canada;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003385-14-ES   Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United States;
      2019   Phase 2   EUCTR2019-000068-86-GB   Austria;Germany;United Kingdom;
      2019   Phase 2   EUCTR2019-000068-86-AT   Austria;Germany;United Kingdom;
      2019   Phase 2   EUCTR2018-003385-14-PT   Austria;Canada;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003385-14-NL   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2019-000068-86-DE   Austria;Germany;United Kingdom;
ALN-61444   
   Alnylam Pharmaceuticals, Inc.
      2015   Phase 1;Phase 2   EUCTR2015-001297-18-GB   United Kingdom;United States;
ALN-77412   
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 1;Phase 2   EUCTR2018-001362-41-GB   Germany;United Kingdom;United States;
ALN-AAT   
   Alnylam Pharmaceuticals, Inc.
      2015   Phase 1;Phase 2   EUCTR2015-001297-18-GB   United Kingdom;United States;
ALN-AAT02   
   Alnylam Pharmaceuticals
      2018   Phase 1/Phase 2   NCT03767829   United Kingdom;
   Alnylam Pharmaceuticals, Inc.
      2018   Phase 1;Phase 2   EUCTR2018-001362-41-GB   Germany;United Kingdom;United States;
API-AAT, AD00370, ARC-AAT, API drug Substance   
   Arrowhead Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-000917-59-SE   Canada;Ireland;Sweden;
   Arrowhead Pharmaceuticals, Inc
      2016   Phase 2   EUCTR2016-000917-59-IE   Canada;Ireland;Sweden;
ARC-AAT Injection   
   Arrowhead Pharmaceuticals
      2016   Phase 2   NCT02900183   Canada;Ireland;Italy;Sweden;
      2015   Phase 1   NCT02363946   Australia;Germany;Netherlands;United Kingdom;
   Arrowhead Pharmaceuticals Inc
      2016   Phase 2   EUCTR2016-000917-59-SE   Canada;Ireland;Sweden;
   Arrowhead Pharmaceuticals, Inc
      2016   Phase 2   EUCTR2016-000917-59-IE   Canada;Ireland;Sweden;
ARO-AAT Injection   
   ARROWHEAD PHARMACEUTICALS
      2019   Phase 2   EUCTR2018-003385-14-IT   Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
   Arrowhead Pharmaceuticals
      2019   Phase 2   NCT03946449   Austria;Germany;United Kingdom;
      2019   Phase 2   NCT03945292   Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United States;
      2018   Phase 1   NCT03362242   New Zealand;
   Arrowhead Pharmaceuticals, Inc.
      2021   Phase 2;Phase 3   EUCTR2018-003385-14-AT   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;Switzerland;United Kingdom;United States;
      2021   Phase 2   EUCTR2018-003385-14-DE   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2;Phase 3   EUCTR2018-003385-14-GB   Canada;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2018-003385-14-SE   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003385-14-IE   Canada;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2;Phase 3   EUCTR2018-003385-14-ES   Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United States;
      2019   Phase 2   EUCTR2019-000068-86-GB   Austria;Germany;United Kingdom;
      2019   Phase 2   EUCTR2019-000068-86-AT   Austria;Germany;United Kingdom;
      2019   Phase 2   EUCTR2018-003385-14-PT   Austria;Canada;Germany;Ireland;Italy;Netherlands;Poland;Portugal;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-003385-14-NL   Austria;Canada;Germany;Ireland;Italy;Netherlands;Portugal;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2019-000068-86-DE   Austria;Germany;United Kingdom;
Abdominal ultrasound   
   University of Florida
      2013   -   NCT01810458   United States;
Aerosolized human Alpha-1 Antitrypsin   
   Kamada Limited
      2011   -   EUCTR2008-005326-36-SE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   Phase 2;Phase 3   EUCTR2008-005326-36-DK   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-NL   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-IE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-DE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2009   Phase 2;Phase 3   EUCTR2008-005326-36-GB   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
Albumin (Human) , United States Pharmacopeia (USP)   
   Grifols Therapeutics Inc.
      2003   Phase 2   NCT00263887   Denmark;Sweden;United Kingdom;
Albuterol inhaler.   
   University of Florida
      2007   -   NCT01851642   United States;
Alpha 1-proteinase inhibitor (human)   
   UHB NHS Foundation Trust
      2008   Phase 2   EUCTR2007-004869-18-GB   United Kingdom;
Alpha-1 Antitrypsin (AAT)   
   Kamada Ltd.
      2020   Phase 3   EUCTR2019-000602-30-SE   Argentina;Belgium;Finland;Ireland;Italy;Netherlands;Sweden;United Kingdom;
      2020   Phase 3   EUCTR2019-000602-30-GB   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
      2020   Phase 3   EUCTR2019-000602-30-FI   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
      2019   Phase 3   EUCTR2019-000602-30-NL   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
Alpha-1 Antitrypsin (human)   
   Michael Campos, MD
      2012   Phase 2   NCT01669421   United States;
Alpha-1 MP   
   Grifols Therapeutics Inc.
      2006   Phase 3   NCT00295061   United States;
   Grifols Therapeutics LLC
      2016   Phase 3   NCT02796937   Australia;Canada;Denmark;Estonia;New Zealand;Poland;Russian Federation;Sweden;United States;
Alpha-1 proteinase inhibitor (human)   
   Grifols Therapeutics Inc.
      2006   Phase 3   NCT00301366   Netherlands;Poland;United Kingdom;United States;
      2006   Phase 3   NCT00295061   United States;
Alpha1-Proteinase Inhibitor (Human)   
   Grifols Therapeutics Inc.
      2015   Phase 3   EUCTR2013-001870-38-DE   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;New Zealand;Poland;Romania;Russian Federation;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-001870-38-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Ireland;Latvia;Lithuania;Netherlands;New Zealand;Norway;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-001870-38-PL   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Ireland;New Zealand;Poland;Romania;Slovakia;Spain;Sweden;United States;
      2013   Phase 3   EUCTR2013-001870-38-ES   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Ireland;Latvia;Lithuania;Netherlands;New Zealand;Norway;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2003   Phase 2   NCT00263887   Denmark;Sweden;United Kingdom;
   Grifols Therapeutics LLC
      2018   Phase 3   EUCTR2015-004110-23-PL   Australia;Canada;Denmark;Estonia;New Zealand;Poland;Russian Federation;Sweden;United States;
      2016   Phase 3   EUCTR2015-004110-23-DK   Argentina;Australia;Brazil;Canada;Denmark;Estonia;France;Germany;New Zealand;Poland;Romania;Russian Federation;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-001870-38-SE   Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001870-38-FI   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001870-38-EE   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001870-38-DK   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
Alvelestat (MPH966)   
   University of Alabama at Birmingham
      2019   Phase 2   NCT03679598   United States;
Alvelestat oral tablet - dose 1   
   Mereo BioPharma
      2018   Phase 2   NCT03636347   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
Alvelestat oral tablet - dose 2   
   Mereo BioPharma
      2018   Phase 2   NCT03636347   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
Alvelestat tosylate   
   Mereo BioPharma 4 Ltd
      2019   Phase 2   EUCTR2018-001309-95-PL   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001309-95-BE   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-SE   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-GB   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-DK   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
Aspirin   
   Columbia University
      2017   Phase 2   NCT03008915   United States;
Belcesiran   
   Dicerna Pharmaceuticals, Inc.
      2021   Phase 2   NCT05146882   New Zealand;
      2021   Phase 2   NCT04764448   Australia;New Zealand;Spain;United Kingdom;
      2019   Phase 1   NCT04174118   New Zealand;Sweden;
Blood draw   
   University of Florida
      2013   -   NCT01810458   United States;
Blood draw.   
   University of Florida
      2007   -   NCT01851642   United States;
Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor   
   Baxalta now part of Shire
      2005   Phase 1   NCT00242385   Australia;New Zealand;
Dose of 60 mg/kg alpha1-proteinase inhibitor   
   Baxalta now part of Shire
      2005   Phase 1   NCT00242385   Australia;New Zealand;
Drug-Carbamazepine (Tegretol XR)   
   Washington University School of Medicine
      2012   Phase 2   NCT01379469   United States;
Fentanyl   
   University of Florida
      2013   -   NCT01810458   United States;
Glassia   
   Impatients N.V. trading as myTomorrows
      2017   -   NCT03172455   -
   Octapharma
      2018   Phase 2   NCT03385395   -
History and physical   
   University of Florida
      2013   -   NCT01810458   United States;
History and physical exam.   
   University of Florida
      2007   -   NCT01851642   United States;
Hyaluronic Acid Inhalation Solution   
   Gerard Turino
      2017   Phase 2   NCT03114020   Canada;United States;
INBRX-101/rhAAT-Fc   
   Inhibrx, Inc.
      2019   Phase 1   NCT03815396   New Zealand;United Kingdom;United States;
Intravenous catheter   
   University of Florida
      2013   -   NCT01810458   United States;
Kamada -AAT for Inhalation or inhaled AAT (AAT)   
   Kamada Ltd.
      2020   Phase 3   EUCTR2019-000602-30-SE   Argentina;Belgium;Finland;Ireland;Italy;Netherlands;Sweden;United Kingdom;
      2020   Phase 3   EUCTR2019-000602-30-GB   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
      2020   Phase 3   EUCTR2019-000602-30-FI   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
      2019   Phase 3   EUCTR2019-000602-30-NL   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
Kamada-AAT for Inhalation,   
   Kamada, Ltd.
      2014   Phase 2   NCT02001688   United States;
Kamada-AAT for inhalation   
   Kamada Limited
      2011   -   EUCTR2008-005326-36-SE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   Phase 2;Phase 3   EUCTR2008-005326-36-DK   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-NL   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-IE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
      2010   -   EUCTR2008-005326-36-DE   Denmark;Germany;Ireland;Netherlands;Sweden;United Kingdom;
Kamada-API   
   Kamada, Ltd.
      2007   Phase 2/Phase 3   NCT00460096   United States;
Lidocaine   
   University of Florida
      2013   -   NCT01810458   United States;
Liver Biopsy   
   University of Florida
      2013   -   NCT01810458   United States;
Lorazepam   
   University of Florida
      2013   -   NCT01810458   United States;
MPH966   
   Mereo BioPharma 4 Ltd
      2019   Phase 2   EUCTR2018-001309-95-PL   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2019   Phase 2   EUCTR2018-001309-95-BE   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-SE   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-GB   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
      2018   Phase 2   EUCTR2018-001309-95-DK   Belgium;Canada;Denmark;Poland;Spain;Sweden;United Kingdom;United States;
Midazolam   
   University of Florida
      2013   -   NCT01810458   United States;
None assigned   
   F. Hoffmann-La Roche Ltd
      2008   Phase 2   EUCTR2004-001688-23-GB   Denmark;Spain;United Kingdom;
      2006   -   EUCTR2004-001688-23-DK   Denmark;Spain;United Kingdom;
      2004   -   EUCTR2004-001688-23-ES   Denmark;Spain;United Kingdom;
OctaAlpha1   
   Octapharma
      2018   Phase 2   NCT03385395   -
Ondansetron   
   University of Florida
      2013   -   NCT01810458   United States;
Oxycodone/Acetaminophen   
   University of Florida
      2013   -   NCT01810458   United States;
PHP-303   
   pH Pharma Inc.
      2020   Phase 2   EUCTR2019-002501-22-GB   United Kingdom;
Prolastin   
   UHB NHS Foundation Trust
      2008   Phase 2   EUCTR2007-004869-18-GB   United Kingdom;
Prolastin-C   
   Grifols Therapeutics Inc.
      2015   Phase 3   EUCTR2013-001870-38-DE   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;New Zealand;Poland;Romania;Russian Federation;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-001870-38-IE   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Ireland;Latvia;Lithuania;Netherlands;New Zealand;Norway;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
      2014   -   EUCTR2013-001870-38-PL   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Ireland;New Zealand;Poland;Romania;Slovakia;Spain;Sweden;United States;
      2013   Phase 3   EUCTR2013-001870-38-ES   Argentina;Australia;Brazil;Canada;Czech Republic;Denmark;Estonia;Finland;France;Germany;Hungary;Ireland;Latvia;Lithuania;Netherlands;New Zealand;Norway;Poland;Serbia;Slovakia;Spain;Sweden;United Kingdom;United States;
   Grifols Therapeutics LLC
      2018   Phase 3   EUCTR2015-004110-23-PL   Australia;Canada;Denmark;Estonia;New Zealand;Poland;Russian Federation;Sweden;United States;
      2016   Phase 3   EUCTR2015-004110-23-DK   Argentina;Australia;Brazil;Canada;Denmark;Estonia;France;Germany;New Zealand;Poland;Romania;Russian Federation;Spain;Sweden;United States;
      2014   Phase 3   EUCTR2013-001870-38-SE   Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2014   Phase 3   EUCTR2013-001870-38-FI   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001870-38-EE   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
      2013   Phase 3   EUCTR2013-001870-38-DK   Argentina;Australia;Brazil;Canada;Denmark;Estonia;Finland;France;Germany;Ireland;Moldova, Republic of;New Zealand;Poland;Romania;Russian Federation;Serbia;Spain;Sweden;United Kingdom;United States;
Prolastin-C,   
   Grifols Therapeutics Inc.
      2010   Phase 2   NCT01213043   United States;
Pulmonary function testing.   
   University of Florida
      2007   -   NCT01851642   United States;
RAAV1-CB-hAAT   
   Applied Genetic Technologies Corp
      2010   Phase 2   NCT01054339   Ireland;United States;
   Applied Genetic Technologies Corporation
      2010   Phase 2   EUCTR2009-014286-20-IE   Ireland;
   University of Massachusetts, Worcester
      2006   Phase 1   NCT00430768   United States;
RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR EXPRESSING THE HUMAN ALPHA-1-ANTITRYPSIN GENE   
   Kamada Ltd.
      2020   Phase 3   EUCTR2019-000602-30-SE   Argentina;Belgium;Finland;Ireland;Italy;Netherlands;Sweden;United Kingdom;
      2019   Phase 3   EUCTR2019-000602-30-NL   Belgium;Finland;Ireland;Netherlands;Sweden;United Kingdom;
RO3300074   
   F. Hoffmann-La Roche Ltd
      2008   Phase 2   EUCTR2004-001688-23-GB   Denmark;Spain;United Kingdom;
      2006   -   EUCTR2004-001688-23-DK   Denmark;Spain;United Kingdom;
      2004   -   EUCTR2004-001688-23-ES   Denmark;Spain;United Kingdom;
Retinoic Acid Receptor gamma Agonist   
   F. Hoffmann-La Roche Ltd
      2008   Phase 2   EUCTR2004-001688-23-GB   Denmark;Spain;United Kingdom;
      2006   -   EUCTR2004-001688-23-DK   Denmark;Spain;United Kingdom;
      2004   -   EUCTR2004-001688-23-ES   Denmark;Spain;United Kingdom;
VX-814   
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   NCT04167345   Canada;Germany;Ireland;United States;
      2020   Phase 2   EUCTR2019-003650-92-SE   Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003650-92-IE   Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003650-92-GB   Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-003650-92-DE   Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
VX-864   
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   EUCTR2019-004881-16-SE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-IE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-GB   Canada;Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-DE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;
VX864   
   Vertex Pharmaceuticals Incorporated
      2020   Phase 2   EUCTR2019-004881-16-SE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-IE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-GB   Canada;Germany;Ireland;Netherlands;Sweden;United Kingdom;United States;
      2020   Phase 2   EUCTR2019-004881-16-DE   Canada;Germany;Ireland;Sweden;United Kingdom;United States;